Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 15/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5420677 | 0.92 | LIPE (0.56) | LIPECHRM1KDM2B | |
| SCHEMBL5426894 | 0.92 | LIPE (0.55) | LIPECHRM1KDM2B | |
| SCHEMBL5419645 | 0.89 | LIPE (0.57) | LIPE | |
| SCHEMBL5420449 | 0.84 | LIPE (0.60) | LIPE | |
| SCHEMBL3749714 | 0.80 | LIPE (0.81) | LIPE | |
| SCHEMBL5423744 | 0.79 | L3MBTL1 (0.46) | LIPELMNAMAPT | |
| SCHEMBL744330 | 0.79 | LIPE (0.67) | LIPECHRM1 | |
| SCHEMBL5437244 | 0.79 | LIPE (0.46) | LIPELMNAMAPTCCR1EPHX2 | |
| SCHEMBL5427248 | 0.78 | LIPE (0.58) | LIPEMAPTCCR1 | |
| SCHEMBL5425145 | 0.77 | KMT2A (0.52) | LIPELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275990-A1 | Heterocyclic Spiro Compound | ONO PHARMACEUTICAL CO., LTD. | 2007-11-29 | — | — | US | disclosed |
| EP-1683797-A1 | HETEROCYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275990-A1 | Heterocyclic Spiro Compound | NR3C2, CBR1, CBR3 | LIPE 3897/4885LMNA 1434/4885MAPT 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.